Last reviewed · How we verify
NCT05726474: ExIC-FEp
Comparison of the Effect of Two Types of Physical Exercises in Patients With Heart Failure With Preserved Ejection Fraction
NA trial testing Combined exercise in Heart Failure in 72 participants. Completed in 15 May 2025.
30 September 2024
Quick facts
| Lead sponsor | University of Castilla-La Mancha |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 23 January 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 15 May 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Combined exercise
- High interval training
Conditions studied
- Heart Failure — all drugs for Heart Failure →
- Physical Exercise — all drugs for Physical Exercise →
- Exercise Capacity — all drugs for Exercise Capacity →
- Diastolic Function — all drugs for Diastolic Function →
Sponsor
University of Castilla-La Mancha
Who can join
40 and older, any sex, with Heart Failure or Physical Exercise. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Heart failure (HF) is a chronic disease with a very important and increasingly severe social and health impact with a prevalence of 6.8% in Spain. HF with preserved ejection fraction (HFpEF) represents approximately 50% of all patients with HF. In the absence of pharmacological treatments that have succeeded in reducing mortality or morbidity in this pathology, it is recommended that interventions be directed at prevention, symptomatic treatment of HF and treatment of comorbidities to avoid exacerbations, thus physical exercise is recognized as an important adjunct in the treatment of HF and is recommended by the guidelines of the American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC). Currently, aerobic exercise is the most studied physical exercise in this population, but in recent years high-intensity interval training (HIIT) and the combination of aerobic exercise with strength training (combined exercise) have emerged. Objectives: The overall objective of this study is to compare the effectiveness of combined training and HIIT on exercise capacity, diastolic function, endothelial function, and arterial stiffness in patients with HFpEF. The specific objectives of this study are: a) to compare the effectiveness of combined training and HIIT on quality of life in patients with HFpEF and b) to analyze the cost-effectiveness of combined training and HIIT versus conventional treatment in patients with HFpEF. Methodology: The ExIC-FEp study will be a single-blind randomized clinical trial with 3 arms (combined exercise, HIIT and a control group), conducted at the Health and Social Research Center of the University of Castilla-La Mancha, to analyze two types of supervised physical exercise in patients with HFpEF for 6 months. Patients with HFpEF will be randomly assigned (1:1:1) to the combined exercise, HIIT or control group. All participants will be examined, at baseline (prior to randomization), at three months (mid-intervention) and at six months (at the end of the intervention). Participants will undergo physical examination, echocardiography, maximal cardiopulmonary stress test, and measurement of endothelial function and arterial stiffness. In addition, sociodemographic variables, quality of life, physical activity, adherence to the Mediterranean diet, strength, spirometry and blood sampling will be measured. Expected scientific contributions: this randomized clinical trial will represent a a significant advance in the scientific evidence available on the efficacy of physical exercise in the treatment of HFpEF, through: (a) transfer of the results to physicians, nurses and patients; (b) dissemination of results through scientific articles, doctoral theses and participation in congresses; (c) press releases and press conferences with the aim of disseminating the research results to the population; (d) dissemination through social networks to improve the social impact; and (e) design and content development of a web page.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Accuracy of the 6-Minute Walk Test for Assessing Functional Capacity in Patients With Heart Failure With Preserved Ejection Fraction and Other Chronic Cardiac Pathologies: Results of the ExIC-FEp Trial and a Meta-Analysis.
Cavero-Redondo I, Saz-Lara A, Bizzozero-Peroni B, Núñez-Martínez L, et al · · 2024 · cited 7× · PMID 38886304 · DOI 10.1186/s40798-024-00740-6 -
Comparative Effect of Two Types of Physical Exercise for the Improvement of Exercise Capacity, Diastolic Function, Endothelial Function and Arterial Stiffness in Participants with Heart Failure with Preserved Ejection Fraction (ExIC-FEp Study): Protocol for a Randomized Controlle
Cavero-Redondo I, Saz-Lara A, Martínez-García I, Bizzozero-Peroni B, et al · · 2023 · cited 4× · PMID 37240641 · DOI 10.3390/jcm12103535
Verify or expand the search:
- PubMed search for NCT05726474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Combined exercise
Trials testing the same drug.
- NCT05736263 — Exercise-induced Glycemic Variations and Hybrid Closed-loop Systems · NA · unknown
- NCT05568004 — The Effect of Different Exercise Types on Migraine Frequency in Individuals With Migraine · NA · completed
- NCT04279652 — Exercise in Children Attention Deficit Hyperactivity Disorder · NA · completed
- NCT03924999 — Comparison of Complete Decongestive Therapy With Intermittent Pneumatic Compression for Treatment of Lipedema · NA · completed
- NCT03529838 — Hemodynamic and Salivary Responses of 12 Weeks of Training With Different Anti-hypertensive · NA · terminated
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other University of Castilla-La Mancha trials
Trials by the same sponsor.
- NCT07487857 — Intensive Somatosensory Camp for Manual Function and Participation in Children With Unilateral Cerebral Palsy · NA · not yet recruiting
- NCT07419035 — Bipolar Radiofrequency for Genitourinary Syndrome of Menopause · NA · not yet recruiting
- NCT07452172 — Lumbar and Gluteal Motor Control in Chronic Low Back Pain · NA · not yet recruiting
- NCT07041944 — HEMImprove 1.0 in Children and Adolescents With Unilateral Cerebral Palsy · NA · not yet recruiting
- NCT07091461 — HOMe-IMprove Telerrehabilitation System · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05726474 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Castilla-La Mancha
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05726474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing